Abstract Background A sedentary lifestyle and poor diet are risk factors for the progression of non-alcoholic fatty liver disease. However, the pathogenesis of hepatic lipid accumulation is not completely understood. Therefore, the present study explored the effects of dietary supplementation of various ratios of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) on a high-fat diet-induced lipid metabolism disorder and the concurrent liver damage. Methods Using high-fat diet-fed C57BL/6 J mice as the animal model, diets of various ratios of DHA/EPA (2:1, 1:1, and 1:2) with an n-6/n-3 ratio of 4:1 were prepared using fish and algae oils enriched in DHA and/or EPA and sunflower seed oils to a small extent instead of the high-fat diet....
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease and a ...
Non-alcoholic fatty liver disease (NAFLD) is triggered by a nutritional-metabolic alteration charact...
Background: Eicosapentaenoic acid (EPA, C20:5n-3), docosahexaenoic acid (DHA, C22:6n-3) and arachido...
Diets containing various docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) ratios protect again...
Fatty liver disease is the most common pathological condition in the liver. Here, we generated high-...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Hepatic steatosis, an early stage of non-alcoholic fatty liver disease, is commonly present in obesi...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Abstract Background Bioactivities of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) depe...
Non-alcoholic fatty liver disease (NAFLD) accompanies obesity and insulin resistance. Recent meta-an...
Non-alcoholic fatty liver disease (NAFLD) accompanies obesity and insulin resistance. Recent meta-an...
BACKGROUND:Low hepatic content of n-3 PUFA has been associated with NAFLD in humans. Whether this is...
Background: N-3 polyunsaturated fatty acids (n-3 PUFAs), in particular eicosapentaenoic acid (EPA) a...
Non-alcoholic fatty liver disease (NAFLD) accompanies obesity and insulin resistance. Recent meta-an...
Non-alcoholic fatty liver disease (NAFLD) is triggered by a nutritional-metabolic alteration charact...
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease and a ...
Non-alcoholic fatty liver disease (NAFLD) is triggered by a nutritional-metabolic alteration charact...
Background: Eicosapentaenoic acid (EPA, C20:5n-3), docosahexaenoic acid (DHA, C22:6n-3) and arachido...
Diets containing various docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) ratios protect again...
Fatty liver disease is the most common pathological condition in the liver. Here, we generated high-...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Hepatic steatosis, an early stage of non-alcoholic fatty liver disease, is commonly present in obesi...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Abstract Background Bioactivities of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) depe...
Non-alcoholic fatty liver disease (NAFLD) accompanies obesity and insulin resistance. Recent meta-an...
Non-alcoholic fatty liver disease (NAFLD) accompanies obesity and insulin resistance. Recent meta-an...
BACKGROUND:Low hepatic content of n-3 PUFA has been associated with NAFLD in humans. Whether this is...
Background: N-3 polyunsaturated fatty acids (n-3 PUFAs), in particular eicosapentaenoic acid (EPA) a...
Non-alcoholic fatty liver disease (NAFLD) accompanies obesity and insulin resistance. Recent meta-an...
Non-alcoholic fatty liver disease (NAFLD) is triggered by a nutritional-metabolic alteration charact...
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease and a ...
Non-alcoholic fatty liver disease (NAFLD) is triggered by a nutritional-metabolic alteration charact...
Background: Eicosapentaenoic acid (EPA, C20:5n-3), docosahexaenoic acid (DHA, C22:6n-3) and arachido...